Vitamin B3

Vitamin B3 is a single name covering two pharmacologically distinct molecules — niacin (nicotinic acid) and nicotinamide (niacinamide) — that share a downstream NAD⁺/NADP⁺ cofactor pool but behave like entirely different drugs at the receptor level. Understanding the split is the whole game: niacin is a lipid-modifying agent that flushes; nicotinamide is a skin and longevity compound that doesn't. They are not interchangeable.

GPR109A Activation and Lipid Modulation (Niacin Only)#

Niacin is a high-affinity agonist at GPR109A (also called HCA2 / HM74A), a Gi-coupled receptor expressed on adipocytes, Langerhans cells, and macrophages. Adipocyte activation suppresses hormone-sensitive lipase, which collapses free fatty acid efflux from fat tissue to the liver. With fewer FFAs arriving at hepatocytes, VLDL assembly slows, ApoB particle output drops, and downstream LDL falls with it.

"Activation of GPR109A by nicotinic acid inhibits intracellular lipolysis in adipocytes, resulting in a marked decrease in plasma free fatty acid concentrations and hepatic triglyceride synthesis." — Kamanna VS, Kashyap ML, American Journal of Cardiology (2008)

This is the mechanism that matters for on-cycle users: when oral AAS or harsh 19-nors crater HDL and inflate ApoB, GPR109A activation is the cheapest pharmacologic lever available to push back. Nicotinamide does not bind GPR109A meaningfully — which is why it produces no flush and no lipid effect. Confusing the two forms is the most common rookie error in this category.

Hepatic DGAT2 Inhibition and ApoB Degradation (Niacin)#

In parallel to the adipocyte effect, niacin acts directly on hepatocytes by inhibiting diacylglycerol acyltransferase-2 (DGAT2) — the terminal enzyme in triglyceride synthesis. With TG synthesis throttled, nascent ApoB particles fail to lipidate properly and are routed to intracellular degradation rather than secretion.

"Niacin decreases the hepatic synthesis of VLDL and its secretion, resulting in decreased circulating levels of LDL. It also inhibits hepatic diacylglycerol acyltransferase-2, a key enzyme for triglyceride synthesis." — Kamanna VS, Kashyap ML, Current Atherosclerosis Reports (2003)

Niacin also raises HDL-C by 15–25% through a separate mechanism: it reduces hepatic uptake of HDL-apoA1 (selective for the apoA1 particle itself, not the cholesterol ester cargo), prolonging HDL residence time and reverse cholesterol transport capacity. This is the practical reason niacin earned its place in cycle-support stacks — HDL recovery is the slowest lipid marker to come back after a harsh oral run, and niacin accelerates it.

NAD⁺ Salvage and DNA Repair (Nicotinamide)#

Nicotinamide bypasses GPR109A entirely and feeds the salvage pathway (NAMPT → NMN → NAD⁺), restoring cellular NAD⁺ pools that get hammered by UV exposure, oxidative stress, and aging. The longevity-adjacent angle here is real but undersold by the marketing around NR and NMN: plain nicotinamide is a robust NAD⁺ substrate with near-complete oral bioavailability for a fraction of the price.

The dermatology payoff is mechanistically downstream. After UV insult, PARP-1 hyperactivates to repair single-strand DNA breaks and burns through cellular NAD⁺ in the process. If NAD⁺ runs out, the cell defaults to apoptosis or carries forward the unrepaired mutations. Nicotinamide refills the pool, keeps nucleotide excision repair running, and reverses UV-induced immunosuppression in the skin — the combination behind the ONTRAC chemoprevention finding.

"Oral nicotinamide at a dose of 500 mg twice daily resulted in a 23% reduction in new nonmelanoma skin cancers compared with placebo after 12 months." — Chen AC, Martin AJ, Choy B, et al., New England Journal of Medicine (2015)

This is the single best-evidenced oral skin intervention outside of retinoids, and it is the reason nicotinamide 500 mg twice daily sits at the bottom of essentially every serious looksmaxxing skin stack — particularly for fair-skinned users, anyone with significant prior sun exposure, and subjects running melanotan-II protocols.

Topical Barrier, Sebum, and Pigment Effects (Nicotinamide)#

Topical niacinamide is mechanistically distinct from oral nicotinamide because the relevant tissue concentration is local rather than systemic. At 2–5% in a serum or cream base, niacinamide upregulates ceramide and free fatty acid synthesis in keratinocytes (improving the lipid component of the stratum corneum barrier), suppresses sebaceous gland output, and — most usefully for AAS users dealing with post-acne hyperpigmentation — inhibits melanosome transfer from melanocytes to surrounding keratinocytes.

"Niacinamide penetrates the stratum corneum effectively at concentrations of 2–5% in topical preparations, improving barrier function, reducing sebum excretion, and attenuating hyperpigmentation." — Wohlrab J, Kreft D, Skin Pharmacology and Physiology (2014)

Practical translation for physique-focused users: 5% topical niacinamide AM and PM stacks cleanly with azelaic acid and tretinoin, handles the oilier skin that comes with on-cycle androgen elevation, and fades the PIH left behind by cycle-driven acne without irritating the barrier.

The Flushing Pathway (Niacin)#

The famous niacin flush is mechanistically separate from the lipid effect — it is GPR109A activation on cutaneous Langerhans cells triggering release of prostaglandin D2 and E2, which cause cutaneous vasodilation, warmth, and the characteristic red, itching skin. It is prostaglandin-mediated, which is why 325 mg aspirin taken 30 minutes prior blunts it effectively, why the response builds tolerance over 2–4 weeks of consistent dosing, and why extended-release formulations dampen it by slowing peak plasma concentration. The flush is harmless. The hepatotoxicity that scales with dose and with the amidation pathway shift in sustained-release products is the real ceiling on long-term niacin dosing — not the flush.

Formulation Matters: IR vs ER vs SR#

The two metabolic pathways niacin runs through — conjugation (generates nicotinuric acid, drives flushing) and amidation (generates nicotinamide and NAD⁺, drives hepatotoxicity) — are saturable and shift with release rate. Faster release favors conjugation (more flush, less liver stress). Slower release favors amidation (less flush, more liver stress).

"Extended-release niacin is absorbed more slowly than immediate-release formulations, with a metabolic shift toward the amidation pathway. This shift increases the risk of hepatotoxicity at higher doses or with sustained-release products." — Knopp RH, Expert Opinion on Pharmacotherapy (2004)

This is why old-school sustained-release (SR) niacin was largely deprecated, why ER (Niaspan) sits in the middle, and why IR niacin — flushy but liver-friendly at moderate doses — remains the cheapest reasonable choice for cycle lipid management when split TID with meals. Flush-free "niacin" (inositol hexanicotinate) does not produce the lipid effect at all and should not be confused with either form.

Common (most users)#

Niacin (nicotinic acid):

• Flushing — the defining side effect. Prostaglandin D2/E2-mediated cutaneous vasodilation peaks ~30 min after an IR dose: warm, red, prickling skin across the face, neck, and upper chest, lasting 15–60 minutes. Mitigation stack: 325 mg aspirin 30 minutes prior, dosing with a meal containing fat, slow titration from 250 mg, and switching to ER (Niaspan) once tolerance is established. The flush attenuates substantially over 2–4 weeks of consistent dosing.
• GI discomfort — mild nausea and dyspepsia at doses above 1 g, almost entirely abolished by splitting IR doses TID with food or moving to ER nightly with a small meal.
• Pruritus / tingling — rides along with the flush; the aspirin pretreatment handles both.

Nicotinamide:

• Essentially asymptomatic at the 500 mg BID ONTRAC dose. No flush, no GI signal, no perceptible acute effect.
• Mild nausea occasionally at single doses above 1 g — split dosing resolves it.

Topical niacinamide:

• Transient stinging or warmth with 10% concentrations on compromised barrier or freshly exfoliated skin. Drop to 4–5% (CeraVe PM, Paula's Choice 4% range) until tolerance builds.

Uncommon (dose-dependent or individual)#

Niacin:

• Transaminase elevation — dose-dependent. Below 1500 mg/day of ER, clinically significant LFT bumps are uncommon; above that the signal climbs. Check AST/ALT/GGT at baseline, week 4, then every 8–12 weeks on chronic dosing. A 2–3x ULN bump warrants a dose cut; sustained elevation warrants discontinuation.
• Worsened insulin sensitivity — niacin modestly raises fasting glucose and HbA1c, more pronounced in subjects with prediabetes or T2D. Check fasting glucose and HbA1c at the same cadence as LFTs; if HbA1c drifts above 5.7 or trends up by 0.3+ on cycle, drop the dose or rotate to bergamot + statin instead.
• Hyperuricemia — niacin competes with uric acid for renal tubular secretion. Uric acid on the panel; if it climbs above ~7 mg/dL or any joint symptoms appear, back off.
• Blunted lipid response on harsh stacks — not a side effect per se, but worth flagging: on tren, anadrol, or superdrol, niacin alone will not rescue ApoB. The protocol calls for a statin layered in once ApoB exceeds ~100 mg/dL despite niacin.

Nicotinamide:

• Mild hepatotoxicity at sustained doses above 3 g/day. The 500 mg BID protocol sits an order of magnitude below this threshold; the risk is only relevant to users freelancing into gram-level chronic dosing.
• Methylation drain at gram-level chronic dosing — NAM is methylated via SAMe for excretion. TMG 500–1000 mg/day is the standard mitigation when nicotinamide is being run hard for NAD⁺ purposes.

Rare but serious#

Niacin:

• Idiosyncratic hepatitis / hepatic failure — the signature serious adverse event, historically tied to sustained-release formulations and dose escalation without monitoring. The amidation pathway dominates as release rate slows, generating hepatotoxic metabolites (Knopp 2004).

"Extended-release niacin is absorbed more slowly than immediate-release formulations, with a metabolic shift toward the amidation pathway. This shift increases the risk of hepatotoxicity at higher doses or with sustained-release products." — Knopp RH, Expert Opinion on Pharmacotherapy (2004)

Warning signs: persistent right-upper-quadrant discomfort, dark urine, jaundice, anorexia, transaminases >5x ULN. Discontinue and get hepatology workup.

• Myopathy in statin combination — present but not dramatically worse than statin monotherapy in modern data. Unexplained muscle pain with elevated CK is the trigger to stop and reassess the stack.
• Severe flush with hypotension — rare, but possible if the first dose is taken on an empty stomach with alcohol or a hot shower stacked on top. Dose with food, skip the sauna for an hour.

Nicotinamide:

• No serious adverse signal has emerged from the ONTRAC dataset or follow-on chemoprevention trials at 500 mg BID. The compound is one of the better-tolerated pharmacologic interventions in the longevity toolbox.

Hard contraindications#

• Active liver disease — both forms at pharmacologic doses. Niacin in particular is off the table with elevated transaminases at baseline.
• Active peptic ulcer disease — niacin aggravates gastric mucosal irritation.
• Active gout or severe hyperuricemia — niacin competes for renal uric acid clearance and will precipitate flares.
• Pregnancy at pharmacologic doses — nutritional intake is unrestricted; gram-level dosing of either form is not. This applies to both niacin and nicotinamide.
• Concurrent high-dose 17α-alkylated orals without LFT monitoring — niacin hepatotoxicity stacks additively with oxandrolone, anadrol, superdrol, and similar. Bloodwork is non-negotiable in this combination.
• "Flush-free niacin" (inositol hexanicotinate) as a substitute — not strictly a contraindication, but a hard practical line: it does not produce the lipid effect and using it instead of real niacin is wasted protocol slack.

Gender and PCT considerations#

Vitamin B3 has no androgenic, estrogenic, or HPTA activity in either form. Dosing is identical across the subject pool — no virilization concern, no aromatization concern, no suppression. No PCT requirement. Niacin is, in fact, commonly retained through PCT and bridge phases specifically because the AAS-induced HDL crater lags AAS clearance by 4–6 weeks, and the lipid panel keeps drifting in the wrong direction even after testosterone normalizes. Nicotinamide for skin chemoprevention runs indefinitely without cycling — the ONTRAC protocol is open-ended, and there is no rationale for breaks.

"Oral nicotinamide at a dose of 500 mg twice daily resulted in a 23% reduction in new nonmelanoma skin cancers compared with placebo after 12 months." — Chen AC, Martin AJ, Choy B, et al., New England Journal of Medicine (2015)